News
ROTOP featured in VentureCapital Magazine
We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key
New Milestone: RoTecPSMA® Approved in Switzerland
RoTecPSMA® Approved in Switzerland – Expanding Access to Advanced Prostate Cancer Diagnostics We are delighted to announce that RoTecPSMA® has received marketing authorization in
Team ROTOP is back from SNMMI 2025 in New Orleans
Team ROTOP is back from SNMMI 2025 in New Orleans and feels energized by the global momentum in radiopharmaceuticals. Team ROTOP - Jens Junker,
First marketing authorization for RoTecPSMA®
First marketing authorization for RoTecPSMA® We are thrilled to announce that RoTecPSMA® has been approved in the United Kingdom! RoTecPSMA® is a technetium-99m cold
ROTOP Pharmaka GmbH Announces Investments from GENUI & SHS Capital and New President, ROTOP USA.
Andrew Varghese, President USA ROTOP Pharmaka GmbH ROTOP Pharmaka GmbH is pleased to announce new investments secured from GENUI & SHS Capital
Radiopharmacy: Radiation made in Saxony
Saxon radiopharmacy network nukliD® strengthens international visibility Today, Thursday 16 January 2025, leading German and international players in the field of radiopharmacy from Saxony
